Skip to main content
NCBI home page
International Journal of Experimental Pathology logoLink to International Journal of Experimental Pathology
. 1991 Dec;72(6):679–693.

Effects of ancrod and rtPA on fibrin accumulation, glomerular inflammation and renal function in nephrotoxic nephritis.

P W Mathieson 1, S Thiru 1, D K Peters 1, D B Oliveira 1
PMCID: PMC2002439  PMID: 1768613

Abstract

We have compared the effects of ancrod and recombinant tissue plasminogen activator (rtPA) on nephrotoxic nephritis induced in pre-immunized rabbits by the administration of nephrotoxic globulin (NTG; sheep anti-rabbit glomerular basement membrane). We used three different doses of NTG: in each experiment three groups of six rabbits were preimmunized with normal sheep globulin and given NTG: group A received no further treatment; group B received rtPA, 2 mg/kg 12 hourly; group C received ancrod 2 U/kg 12 hourly. Animals were bled daily for estimation of plasma fibrinogen and serum creatinine, then killed on day 5 and kidneys removed for histology. 1 ml/kg of NTG caused massive glomerular necrosis, all three groups having severe renal failure. With 0.5 ml/kg of NTG, ancrod and rtPA both effectively prevented fibrin deposition in Bowman's space, but all animals had severe proliferative glomerulonephritis and marked renal failure. With 0.25 ml/kg of NTG, control animals developed severe proliferative nephritis and advanced renal failure, ancrod provided almost complete protection, and the rtPA group had renal injury and functional impairment intermediate between the other two groups. We conclude that renal failure in severe nephrotoxic nephritis is fibrin-independent, but in less fulminant nephritis renal function can be protected by defibrination with ancrod. rtPA is capable of reducing glomerular fibrin accumulation as effectively as ancrod, but provides inferior protection of renal function.

Full text

PDF
679

Images in this article

684p684-a
on p.684
685p685-a
on p.685
686p686-a
on p.686
687Fig. 3
on p.687
689p689-a
on p.689
690Fig. 6
on p.690

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bell W. R., Pitney W. R., Goodwin J. F. Therapeutic defibrination in the treatment of thrombotic disease. Lancet. 1968 Mar 9;1(7541):490–493. doi: 10.1016/s0140-6736(68)91465-7. [DOI] [PubMed] [Google Scholar]
  2. Bergstein J. M. Tissue plasminogen activator therapy of glomerular thrombi in the Shwartzman reaction. Kidney Int. 1989 Jan;35(1):14–18. doi: 10.1038/ki.1989.2. [DOI] [PubMed] [Google Scholar]
  3. HALPERN B., MILLIEZ P., LAGRUE G., FRAY A., MORARD J. C. PROTECTIVE ACTION OF HEPARIN IN EXPERIMENTAL IMMUNE NEPHRITIS. Nature. 1965 Jan 16;205:257–259. doi: 10.1038/205257a0. [DOI] [PubMed] [Google Scholar]
  4. KLEINERMAN J. Effects of heparin on experimental nephritis in rabbits. Lab Invest. 1954 Nov-Dec;3(6):495–508. [PubMed] [Google Scholar]
  5. Kim S., Wadhwa N. K., Kant K. S., Pollak V. E., Glas-Greenwalt P., Weiss M. A., Hong C. G. Fibrinolysis in glomerulonephritis treated with ancrod: renal functional, immunologic and histopathologic effects. Q J Med. 1988 Nov;69(259):879–905. [PubMed] [Google Scholar]
  6. McGiven A. R. Blood coagulation and the effect of warfarin treatment on renal disease in NZB-NZW mice. Br J Exp Pathol. 1967 Oct;48(5):552–555. [PMC free article] [PubMed] [Google Scholar]
  7. Naish P. F., Evans D. J., Peters D. K. The effects of defibrination with ancrod in experimental allergic glomerular injury. Clin Exp Immunol. 1975 May;20(2):303–309. [PMC free article] [PubMed] [Google Scholar]
  9. Pollak V. E., Glueck H. I., Weiss M. A., Lebron-Berges A., Miller M. A. Defibrination with ancrod in glomerulonephritis: effects on clinical and histologic findings and on blood coagulation. Am J Nephrol. 1982;2(4):195–207. doi: 10.1159/000166646. [DOI] [PubMed] [Google Scholar]
  10. Salant D. J. Immunopathogenesis of crescentic glomerulonephritis and lung purpura. Kidney Int. 1987 Sep;32(3):408–425. doi: 10.1038/ki.1987.225. [DOI] [PubMed] [Google Scholar]
  11. Segasothy M., Kong C. T., Morad Z., Suleiman A. B., Phang K. S. Rapidly progressive glomerulonephritis: treatment with combined immunosuppression and anticoagulation with arvin. Singapore Med J. 1986 Oct;27(5):422–427. [PubMed] [Google Scholar]
  12. Thomson N. M., Simpson I. J., Peters D. K. A quantitative evaluation of anticoagulants in experimental nephrotoxic nephritis. Clin Exp Immunol. 1975 Feb;19(2):301–308. [PMC free article] [PubMed] [Google Scholar]
  13. Tipping P. G., Holdsworth S. R. Fibrinolytic therapy with streptokinase for established experimental glomerulonephritis. Nephron. 1986;43(4):258–264. doi: 10.1159/000183851. [DOI] [PubMed] [Google Scholar]
  14. VASSALLI P., MCCLUSKEY R. T. THE PATHOGENIC ROLE OF THE COAGULATION PROCESS IN RABBIT MASUGI NEPHRITIS. Am J Pathol. 1964 Oct;45:653–677. [PMC free article] [PubMed] [Google Scholar]

Articles from International Journal of Experimental Pathology are provided here courtesy of Wiley

RESOURCES